Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo

9 Jul 2015

Abstract excerpt

Contains fulltext : 155109.pdf (Publisher’s version ) (Open Access)

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Monoclonal and Polyclonal Antibodies Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 26160188
DOI: 10.1182/blood-2015-03-637645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivoPMID 26160188Read ↗

Eculizumab fails to inhibit generation of C5a in vivoSemantic proximity Read ↗

The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeuticsSemantic proximity Read ↗

C1- inhibitors and their genes: an update.Semantic proximity Read ↗

Structure, function and control of complement C5 and its proteolytic fragments.Semantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

[C5a inhibitor deficiency].Semantic proximity Read ↗

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19Semantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

C1, MBL–MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammationSemantic proximity Read ↗

The Complement C5a-C5aR1 GPCR Axis in COVID-19 TherapeuticsSemantic proximity Read ↗

The case for complement component 5 as a target in neurodegenerative diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.